TIDMAMYT
Amryt to Report Q2 2021 Results and Host Conference Call &
Webcast on August 6
DUBLIN, Ireland, and Boston MA, July 12, 2021, Amryt (Nasdaq:
AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical
company dedicated to acquiring, developing and commercializing
novel treatments for rare diseases, today announces that its
unaudited financial results for the second quarter 2021 will be
released on Friday, August 6, 2021 at 0700 EDT/1200 BST.
Amryt will host a conference call and webcast for analysts and
investors on August 6 at 0830 EDT/1330 BST.
Webcast Player URL:
https://www.globenewswire.com/Tracker?data=ejfEM7jom63rl5ctduothPwGRxuDnieOXfU4QFEcBIs9-DzWNC0rDXqAAjBhPOlw4yu3QxEp8PWl9WTKed1yI7g-fWqyJecAcOV6Y5-ayGQg81fjuLa0hOvBJBuSKCG9xCIGuQpT_5Ci2C2vZVu5_w==
https://edge.media-server.com/mmc/p/kvzqsgbt
Telephone Dial in details:
United States +1 646 787 1226
------------------
United Kingdom +44 (0) 203 009 5709
Ireland +353 (1) 506 0626
Confirmation Code 3486585
A playback facility will be available from August 6, 2021 at
1330 EDT / 1830 BST -- August 13, 2021 at 1330 EDT / 1830 BST.
Access details for the playback facility are as follows:
Confirmation Code: 3486585 | US: + 1 917 677 7532 | UK: +44 (0) 333
300 9785 | Ireland : +353 (1) 553 8777.
About Amryt
Amryt is a global commercial-stage biopharmaceutical company
focused on acquiring, developing and commercializing innovative
treatments to help improve the lives of patients with rare and
orphan diseases. Amryt comprises a strong and growing portfolio of
commercial and development assets.
Amryt's commercial business comprises two orphan disease
products -- metreleptin (Myalept(R)/ Myalepta(R)) and lomitapide
(Juxtapid(R)/ Lojuxta(R)).
Myalept(R)/Myalepta(R) (metreleptin) is approved in the US
(under the trade name Myalept(R)) as an adjunct to diet as
replacement therapy to treat the complications of leptin deficiency
in patients with congenital or acquired generalized lipodystrophy
(GL) and in the EU (under the trade name Myalepta(R)) as an adjunct
to diet for the treatment of leptin deficiency in patients with
congenital or acquired GL in adults and children two years of age
and above and familial or acquired partial lipodystrophy (PL) in
adults and children 12 years of age and above for whom standard
treatments have failed to achieve adequate metabolic control. For
additional information, please follow this
https://www.globenewswire.com/Tracker?data=N9RFlO-ZpkOtdz-hcMKYs_gOwjzFFOhhWMvUYzjUMxabQl8KFBqnfNsuGIv6TvMH0d8k9k4QaHe0mBThjy_RGhZ3_tCqLCaHXmmwzfAdkAJJF68tNUMe6AnuQ_mlLXgmdmm6wEMLmZxXNBd8lXhLfwbB3v_LIB8BiMoF6HebjCI=
link.
Juxtapid(R)/Lojuxta(R) (lomitapide) is approved as an adjunct to
a low-fat diet and other lipid-lowering medicinal products for
adults with the rare cholesterol disorder, Homozygous Familial
Hypercholesterolaemia ("HoFH") in the US, Canada, Colombia,
Argentina and Japan (under the trade name Juxtapid(R)) and in the
EU, Israel and Brazil (under the trade name Lojuxta(R)). For
additional information, please follow this
https://www.globenewswire.com/Tracker?data=N9RFlO-ZpkOtdz-hcMKYsyMb230ySlcGkcKSccsHyBX-ZSMJy0eXefQAB7SFx342Gag9vbxQsCZTkMWBZnc9iVh3Q0C5bPsK_GbrivWg7-U=
link.
Amryt's lead development candidate, Oleogel-S10 (Filsuvez(R)) is
a potential treatment for the cutaneous manifestations of
Junctional and Dystrophic Epidermolysis Bullosa ("EB"), a rare and
distressing genetic skin disorder affecting young children and
adults for which there is currently no approved treatment.
Filsuvez(R) has been selected as the brand name for Oleogel-S10.
The product does not currently have regulatory approval to treat
EB. In June 2021, Amryt received confirmation from the FDA that its
NDA for Oleogel-S10 had been accepted and granted priority
review.
Amryt's pre-clinical gene therapy platform, AP103, offers a
potential treatment for patients with Dystrophic EB, and is also
potentially relevant to other genetic disorders.
For more information on Amryt, including products, please visit
https://www.globenewswire.com/Tracker?data=Hsc125XP-ZDOYBWdMuA2bkxaBBcbVVzVaKOt-ZahLMVuQ6eb7Iu1g7BqaLNE51bx2xGRDbfEfOA0Tr2nwTjRHlr4QXmfxHikjhjgmqoUM90=
www.amrytpharma.com.
The person making this notification on behalf of Amryt is Rory
Nealon, CFO/COO and Company Secretary.
Financial Advisors
Shore Capital (Edward Mansfield, Daniel Bush, John More) are
NOMAD and Joint Broker to Amryt in the UK. Stifel (Ben Maddison)
are Joint Broker to the company in the UK.
Forward-Looking Statements
This press release may contain forward-looking statements
containing the words "expect", "anticipate", "intends", "plan",
"estimate", "aim", "forecast", "project" and similar expressions
(or their negative) identify certain of these forward-looking
statements. The forward-looking statements in this announcement are
based on numerous assumptions and Amryt's present and future
business strategies and the environment in which Amryt expects to
operate in the future. Forward-looking statements involve inherent
known and unknown risks, uncertainties and contingencies because
they relate to events and depend on circumstances that may or may
not occur in the future and may cause the actual results,
performance or achievements to be materially different from those
expressed or implied by such forward-looking statements. These
statements are not guarantees of future performance or the ability
to identify and consummate investments. Many of these risks and
uncertainties relate to factors that are beyond each of Amryt's
ability to control or estimate precisely, such as future market
conditions, the course of the COVID-19 pandemic, currency
fluctuations, the behaviour of other market participants, the
outcome of clinical trials, the actions of regulators and other
factors such as Amryt's ability to obtain financing, changes in the
political, social and regulatory framework in which Amryt operates
or in economic, technological or consumer trends or conditions.
Past performance should not be taken as an indication or guarantee
of future results, and no representation or warranty, express or
implied, is made regarding future performance. No person is under
any obligation to update or keep current the information contained
in this announcement or to provide the recipient of it with access
to any additional relevant information that may arise in connection
with it. Such forward-looking statements reflect the Company's
current beliefs and assumptions and are based on information
currently available to management.
Contacts
Joe Wiley, CEO / Rory Nealon, CFO/COO, +353 (1) 518 0200,
https://www.globenewswire.com/Tracker?data=c3GDGZIpKnm6K6mf8td0ufYteKNpucVVvYGBIbi_sOzXaWm-Oj1iOnA7cZumtiAo4ihrLDmJ9fC83Px_JEMHI09tn5qqCmj5zYzcitU9wDY=
ir@amrytpharma.com
Edward Mansfield, Shore Capital, NOMAD, +44 (0) 207 468 7906,
edward.mansfield@shorecap.co.uk
Tim McCarthy, LifeSci Advisors, LLC, +1 (212) 915 2564,
tim@lifesciadvisors.com
Amber Fennell, Consilium Strategic Communications, +44 (0) 203
709 5700, fennell@consilium-comms.com
https://www.globenewswire.com/Tracker?data=veLR_tI5KY6YChFmZ_w28A0AFlRpMb3SUQrLicwo5PR9coyzsSjjJb3eHpUqXR8Sa3KqS98MU87IzDvIPGEx_SdCTPjTCum13og60YhWyPw3Sf5BX_lBzGo1bAfqKqo7
(END) Dow Jones Newswires
July 12, 2021 07:00 ET (11:00 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Amryt Pharma (LSE:AMYT)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025
Amryt Pharma (LSE:AMYT)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025
